U1-snRNP antibodies, also referred to as U1-RNP and Smith (Sm)/RNP, target 3 components of the U1 small nuclear ribonucleoprotein complex: U1-snRNP RNP A, U1-snRNP RNP C, and U1-snRNP RNP-70kd.
These antibodies, found in 2% to 14% of SSc patients, are more frequent in lcSSc than in dcSSc.
The 2 main types of SSc are defined according to the pattern of skin involvement: limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc).
In lcSSc, skin thickening is present distal to the elbows and knees, and facial skin thickening may or may not be present. In contrast, dcSSc is characterized by thickening of the skin of the whole extremity, as well as that of the anterior chest, abdomen, and back, with or without facial skin involvement. Multiple organs, including the heart, lungs, gastrointestinal tract, and kidneys, can be affected in both forms, though organ involvement is generally less severe in lcSSc.
CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) occurs frequently in lcSSC but can also occur in longstanding dcSSc.
The antibodies are also found in patients with other autoimmune diseases, including approximately 90% of patients with mixed connective tissue disease.
Patients with U1-snRNP antibodies tend to have less prominent skin thickness and less renal involvement, but have increased risk of PAH, arthritis, and esophageal dysfunction.
Overall, the presence of U1-snRNP antibodies is associated with a good response to corticosteroids and a favorable prognosis.
Clinical Characteristics Associated With Autoantibodies Used in the Diagnosis and Classification of Systemic Sclerosisa:
Antibody |
Prevalence in SSc, % |
Presence in other autoimmune diseases |
SSc type most likely |
Clinical associations |
Relative SSc prognosis |
ANA |
85-95 |
Common |
Does not help differentiate type |
Most common in rheumatic diseases |
Varies |
Centromere A or B |
20-40 b |
Uncommon |
lcSSc |
PAH, calcinosis, digital ischemia, intestinal involvement |
Better |
Ku |
1.5-5 |
Common |
Overlap syndromes or lcSSc |
Muscle and joint involvement |
Unclear |
PM/Scl-75 or PM/Scl-100 |
2-11 |
Common |
SSc-myositis overlap syndrome or lcSSc |
Muscle and joint involvement, calcinosis; GI and lung involvement for those with PM/Scl-75 |
Better |
RNA Polymerase III |
7-41 |
Rare |
dcSSc |
Renal crisis, progressive skin thickening, GAVE, malignancy |
Poorer |
Scl-70 |
9.4-71 b |
Rare |
dcSSc |
Severe pulmonary fibrosis, cardiac involvement, renal crisis, digital ulcers |
Poorer |
Th/To |
2-5 |
Rare |
lcSSc |
Pulmonary involvement |
Poorer |
U1-snRNP |
2-14 |
Common (90% in patients with MCTD) |
lcSSc |
PAH, arthritis, esophageal dysfunction |
Better |
U3-RNP (Fibrillarin) |
4-10 b |
Rare |
dcSSc |
Multiorgan involvement, PAH |
Poorer |
ANA, antinuclear antibodies; dcSSc, diffuse cutaneous systemic sclerosis; GAVE, gastric antral vascular ectasia; GI, gastrointestinal; lcSSc, limited cutaneous systemic sclerosis; MCTD, mixed connective tissue disease; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis. | |
a | Data presented in this table have been compiled from the cited references. It is important to note that autoantibody frequency in SSc as well as other autoimmune diseases varies with sex, ethnicity, and population studied. |
b | In the United States, prevalence has been shown to vary across ethnicities. |
References:
Stochmal A, Czuwara J, Trojanowska M, et al. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40-51. doi:10.1007/s12016-018-8718-8
Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12(3):340-354. doi:10.1016/j.autrev.2012.05.011
Hamaguchi Y, Takehara K. Anti-nuclear autoantibodies in systemic sclerosis: news and perspectives. J Scleroderma Relat Disord. 2018;3(3):201-213. doi:10.1177/2397198318783930
Young A, Khanna D. Systemic sclerosis: commonly asked questions by rheumatologists. J Clin Rheumatol. 2015;21(3):149-155. doi:10.1097/RHU.0000000000000232
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/s0140-6736(17)30933-9
Understand and improve your laboratory results with our health dashboard.
Upload your lab reports and get your interpretation today.
Our technology helps to understand, combine, track, organize, and act on your medical lab test results.
These antibodies, found in 2% to 14% of SSc patients, are more frequent in lcSSc than in dcSSc.
The 2 main types of SSc are defined according to the pattern of skin involvement: limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc).
In lcSSc, skin thickening is present distal to the elbows and knees, and facial skin thickening may or may not be present. In contrast, dcSSc is characterized by thickening of the skin of the whole extremity, as well as that of the anterior chest, abdomen, and back, with or without facial skin involvement. Multiple organs, including the heart, lungs, gastrointestinal tract, and kidneys, can be affected in both forms, though organ involvement is generally less severe in lcSSc.
CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) occurs frequently in lcSSC but can also occur in longstanding dcSSc.
The antibodies are also found in patients with other autoimmune diseases, including approximately 90% of patients with mixed connective tissue disease.
Patients with U1-snRNP antibodies tend to have less prominent skin thickness and less renal involvement, but have increased risk of PAH, arthritis, and esophageal dysfunction.
Overall, the presence of U1-snRNP antibodies is associated with a good response to corticosteroids and a favorable prognosis.
Interpret Your Lab Results
Upload your lab report, and we'll interpret and provide you with recommendations today.
Get StartedOur specialized data entry service is designed to seamlessly integrate your laboratory results into your private dashboard. Just send in your lab test results—whether it's an image or a file—and our skilled data entry team will handle the rest. We accommodate various file formats like PDFs, JPGs, and Excel.
The first report is complimentary. After that, the data entry service is priced at $15 per report, unless it's part of your subscribed plan. It's an ideal solution whether you have numerous reports to upload or if your schedule doesn't permit self-data entry.
We strive to make the data entry process easy for you. Whether by offering dozens of templates to choose from that pre-populate the most popular laboratory panels or by giving you instant feedback on the entered values. Our data entry forms are an easy, fast, and convenient way to enter the reports yourself. There is no limit on how many lab reports you can upload.
Personal plans
track personal results
Professional Plan
track multiple client's results
$15/month
$250/once
own it for life
$45/month
for health professionals
Personal Account
$15/month
for personal lab results
$250/once
own it for life
Level up your lab report analysis with our Pro plan, built for health practitioners like you.
Health Business Account
$45/month
Unlock additional Pro plans when you sign up.
At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.